SUNY Oneonta to offer student support program
This fall, SUNY Oneonta will be part of the expansion of a SUNY system-wide retention program to provide students with additional academic, financial and personal support to stay on track and graduate on time.
According to a news release from the university, 150 students at SUNY Oneonta will be eligible this fall semester to receive financial resources and "wrap around support" to remove barriers to full-time study, help gain and maintain academic momentum and create a connected community among students.
Any SUNY student who receives at least $1 of federal Pell or New York state grant aid (TAP or Excelsior) is likely to be eligible for the new Advancing Completion through Engagement program.
The ACE Program is part of a larger effort recently championed in the 2025-2026 state budget, according to the release. A $12 million investment will sustain and expand the ASAP|ACE retention and completion programs to reach 6,000 students across New York state next year with a goal of 10,000 students within two years.
'SUNY Oneonta is committed to connecting our students with all the means necessary to learn and graduate. Advising and counseling our students to meet their unique situations creates an inclusive environment that benefits all,' SUNY Oneonta President Alberto Cardelle said. 'We are excited to offer SUNY ACE, an evidence-based retention program, as one more meaningful investment in our students' success.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Three Mississippi-based HBCUs look to expand AI Education
The post Three Mississippi-based HBCUs look to expand AI Education appeared first on ClutchPoints. A $9.1 million higher education grant awarded to the state of Mississippi will help three HBCUs to increase entrepreneurship, job training, and artificial intelligence (AI) education. Jackson State University, Tougaloo College, and Alcorn State University will benefit from the multi-million-dollar grant. Governor Tate Reeves announced the funds through the Mississippi AI Talent Accelerator Program (MAI-TAP) on June 12, 2025, with the goal of bolstering the state's workforce and economic future, according to WJTV 12 News. To increase its influence, each institution will look for private financing and resources in addition to public assistance. 'This is another bold step forward for Mississippi,' Reeves said. 'We're not just preparing for the future—we're building it. This investment will help to ensure that Mississippians are equipped with the skills needed to thrive in a rapidly evolving digital economy.' The Executive On Roster (XOR) program, which will spearhead a statewide effort to introduce students, educators, and entrepreneurs to emerging technology through experiential learning, was granted $1.3 million to Jackson State University, administered by AccelerateMS. Consulting teams of Jackson State students will also strive to provide small firms AI-powered assistance. 'We are grateful for this investment in Jackson State University's mission to expand access to emerging fields,' JSU Interim President Denise Gregory, Ph.D., said in a news release. 'This grant affirms the quality of our faculty and programs and allows us to give students the knowledge and experience to navigate and contribute to the world they are entering. It's another step forward in our work to serve students and communities through innovation and opportunity.' According to WJTV, Tougaloo College received $1.08 million to create a fund to provide students in all disciplines with access to AI-related ideas and employ new faculty members in the fields of AI and machine learning. $1.15 million was awarded to Alcorn State University to train people in southwestern Mississippi in digital literacy and artificial intelligence and to use its School of Nursing to implement telehealth tools to increase access to healthcare in underprivileged rural areas. The University of Southern Mississippi, Mississippi State University, and Mississippi College were among the other state universities that received awards. The funding comes in the wake of an executive order signed by President Donald Trump on April 23 that 'established' a White House Initiative to support HBCUs' excellence and innovation.' Expanding access to federal and state grants, supporting institutional and workforce development in sectors like technology, health care, manufacturing, and finance, and establishing an annual White House HBCU Summit to establish partnerships and set goals are all part of the initiative's mission to improve educational quality through private-sector partnerships. 'HBCUs are essential to fostering opportunity, economic mobility, and national competitiveness, serving as engines of success for American students,' a White House press release stated. 'HBCUs have made extraordinary contributions to the general welfare and prosperity of the United States while producing many leaders in business, government, academia, and the military. Nearly 300,000 individuals annually pursue their dreams at HBCUs throughout the United States. These institutions generate $16.5 billion in annual economic impact and support over 136,000 jobs, strengthening communities and the nation.' Related: 'Love Island' winner nabs role in HBCU series on Keke Palmer network Related: Marva Johnson officially named 13th president of Florida AM
Yahoo
5 days ago
- Yahoo
Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company's recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System. The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations. The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. 'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.' About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use. For more information, please visit: CONTACT: Media Contact contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company's recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System. The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations. The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. 'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.' About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use. For more information, please visit: CONTACT: Media Contact contact@
